VSIG10抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12385(VSIG10 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12385(VSIG10 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

VSIG10 (V-set and immunoglobulin domain-containing protein 10), also known as CTHRC3 (collagen triple helix repeat-containing protein 3), is a transmembrane protein belonging to the immunoglobulin superfamily. Structurally, it contains an extracellular V-set Ig-like domain and a collagen triple helix repeat, suggesting roles in cell adhesion and extracellular matrix interactions. VSIG10 is expressed in various tissues, including the brain, retina, and reproductive organs, with emerging evidence implicating it in neurodevelopment, retinal function, and immune regulation.

Antibodies targeting VSIG10 are primarily used as research tools to investigate its expression patterns, molecular interactions, and biological functions. In disease contexts, VSIG10 has been linked to cancer progression, particularly in gliomas and colorectal cancers, where its overexpression correlates with tumor invasiveness and poor prognosis. Additionally, studies suggest its involvement in immune modulation, potentially influencing T-cell activity and inflammatory responses.

VSIG10 antibodies enable detection via techniques like immunohistochemistry, Western blotting, and flow cytometry, aiding in mechanistic studies and biomarker validation. Recent research also explores its therapeutic potential, with antibody-based strategies targeting VSIG10 in preclinical models to disrupt oncogenic signaling or modulate immune checkpoints. Despite these advances, the full scope of VSIG10's physiological and pathological roles remains under investigation, highlighting the continued importance of specific antibodies in elucidating its multifaceted biology.